BDBM259406 US10457647, Example 5::US11180460, Example 5::US11673868, Example 5::US9512084, 5

SMILES Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC1CCN(CC1)C(=O)C=C

InChI Key InChIKey=SQPBHMYMFCISEC-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 259406   

TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259406(US10457647, Example 5 | US11180460, Example 5 | US...)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259406(US10457647, Example 5 | US11180460, Example 5 | US...)
Affinity DataIC50:  4nMAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259406(US10457647, Example 5 | US11180460, Example 5 | US...)
Affinity DataIC50:  201nMAssay Description:Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259406(US10457647, Example 5 | US11180460, Example 5 | US...)
Affinity DataIC50:  4nMAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259406(US10457647, Example 5 | US11180460, Example 5 | US...)
Affinity DataIC50:  3.70nMAssay Description:Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259406(US10457647, Example 5 | US11180460, Example 5 | US...)
Affinity DataIC50:  4nMAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259406(US10457647, Example 5 | US11180460, Example 5 | US...)
Affinity DataIC50:  12nMAssay Description:Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HT...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed